Joanna Stanislawiak-Rudowicz

Dr. Joanna Stanislawiak-Rudowicz


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2023 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
JSJoanna Stanislawiak-Rudowicz
Joanna Stanislawiak-Rudowicz
AKAgnieszka Karbownik
Agnieszka Karbownik
DSDanuta Szkutnik-Fiedler
Danuta Szkutnik-Fiedler
FOFilip Otto
Filip Otto
TGTomasz Grabowski
Tomasz Grabowski
ESEdyta Szałek
Edyta Szałek
Objective: Olaparib is a PARP (poly-ADP-ribose polymerase) inhibitor used for maintenance therapy in BRCA-mutated cancers. Metformin is a first-choice drug used in the treatment of type 2 diabetes. Both drugs are commonly co-administered to oncologic patients with add-on type 2 diabetes mellitus. Olaparib is metabolized by the CYP3A4 enzyme, which may be inhibited by metformin through the Pregnane X Receptor. In vitro studies have shown that olaparib inhibits the following metformin transporters: OCT1, MATE1, and MATE2K. The aim of the study was to assess the influence of ‘the perpetrator drug’ on the pharmacokinetic (PK) parameters of ‘the victim drug’ after a single dose. To evaluate the effect, the AUC0→∞ (area under the curve) ratio was determined (the ratio between AUC0→∞ in the presence of the perpetrator and AUC0→∞ without the presence of the perpetrator). Methods: Male Wistar rats were assigned to three groups (eight animals in each group), which were orally administered: metformin and olaparib (IMET+OLA), vehiculum with metformin (IIMET), and vehiculum with olaparib (IIIOLA). Blood samples were collected after 24 h. HPLC was applied to measure the concentrations of olaparib and metformin. The PK parameters were calculated in a non-compartmental model. Results: Metformin did not affect the olaparib PK parameters. The AUC0→∞ IMET+OLA/IIIOLA ratio was 0.99. Olaparib significantly increased the metformin Cmax (by 177.8%), AUC0→t (by 159.8%), and AUC0→∞ (by 74.1%). The AUC0→∞ IMET+OLA/IIMET ratio was 1.74. Conclusions: A single dose of metformin did not affect the PK parameters of olaparib, nor did it inhibit the olaparib metabolism, but olaparib significantly changed the metformin pharmacokinetics, which may be of clinical importance.

26 February 2019 in Advances in Medical Sciences
Verified
Journal Article
Closed access
MSMonika Szarszewska
Monika Szarszewska
AMAnna Markowska
Anna Markowska
RJRobert Jach
Robert Jach
AMAndrzej Marszałek
Andrzej Marszałek
VFVioletta Filas
Violetta Filas
PKPawel Knapp
Pawel Knapp

1 January 2022
Verified
Journal Article
Closed access
JSJoanna Stanislawiak-Rudowicz
Joanna Stanislawiak-Rudowicz
ESE. Szalek
E. Szalek
MGM. Grzebalska
M. Grzebalska
HUH. Urjasz
H. Urjasz
MMM. Michalak
M. Michalak
EGE. Grzeskowiak
E. Grzeskowiak

8 January 2020 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
AKAgnieszka Karbownik
Agnieszka Karbownik
ASAnna Stachowiak
Anna Stachowiak
HUHanna Urjasz
Hanna Urjasz
KSKatarzyna Sobańska
Katarzyna Sobańska
ASAgnieszka Szczecińska
Agnieszka Szczecińska
ESEdyta Szałek
Edyta Szałek
Background Diabetes reduces the activity of CYP3A4 and may increase the exposure for the drugs metabolized by the isoenzyme. Sorafenib is a multi-targeted tyrosine kinase inhibitor (TKI), used for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma and radioactive iodine resistant thyroid carcinoma. The TKI undergoes CYP3A4-dependent oxidative transformation, which may be influenced by hyperglycaemia. The aim of the study was to compare the oxidation for sorafenib between healthy and streptozotocin-induced diabetic rats. Additionally, the effect of sorafenib on glucose levels was investigated. Methods The rats were assigned to the groups: streptozotocin-induced diabetic (DG, n = 8) or healthy (HG, n = 8). The rats received sorafenib orally as a single dose of 100 mg/kg. The plasma concentrations of sorafenib and its metabolite N-oxide were measured with the validated high-performance liquid chromatography with ultraviolet detection. Results The difference between groups in Cmax and AUC0−t values for sorafenib were significant (p = 0.0004, p = 0.0104), and similarly for the metabolite (p = 0.0008, p = 0.0011). Greater exposure for the parent drug and analysed metabolite was achieved in diabetic group. However, the Cmax, AUC0−t, and AUC0−∞ ratios between the metabolite and sorafenib were similar in both groups. The significant reduction of glycaemia was observed only in the diabetic animals. Conclusion The findings of the study provide evidence that diabetes significantly influence on the exposition for sorafenib and its metabolite, but similar ratios N-oxide/sorafenib for AUC and Cmax in healthy and diabetic animals suggest that oxidation of the TKI is rather unchanged. Additionally, sorafenib-associated hypoglycaemia was confirmed in diabetic animals.

22 January 2024 in Reports of Practical Oncology and Radiotherapy
Verified
Journal Article
Open access
PDF file
JSJoanna Stanislawiak-Rudowicz
Joanna Stanislawiak-Rudowicz
ESEdyta Szałek
Edyta Szałek
AAAneta Adamiak
Aneta Adamiak
HUHanna Urjasz
Hanna Urjasz
BWBarbara Więckowska
Barbara Więckowska
RMRadoslaw Mądry
Radoslaw Mądry
Background: Olaparib is the first poly(ADP-ribose) polymerase inhibitor approved in Europe for the treatment of platinum-sensitive patients with newly diagnosed or recurrent platinum-sensitive ovarian cancer with a confirmed BRCA mutation or homologous recombination deficiency (HRD). Epidemiological studies have shown an incompatible association between ovarian cancer and obesity, but there have also been scientific reports indicating that obesity, especially severe obesity, increases the risk of ovarian cancer. Olaparib has a wide range of side effects, especially anaemia and neutropenia, which may lead to dose reduction or therapy discontinuation. Therefore, therapeutic drug monitoring (TDM) is recommended. The aim of the study was a retrospective analysis of threshold value of the trough concentration of olaparib (Ctrough) and haematological adverse reactions after olaparib treatment (300 mg/12 h) in excess-weight and normal body mass index (BMI) patients with ovarian cancer. Materials and methods: The pilot study was conducted on 38 ovarian cancer patients who were divided into two groups: I — normal BMI patients (BMI = 18.5–24.9 kg/m2; n = 14), II — excess-weight patients, i.e. overweight and obese patients (BMI ≥ 25 kg/m2; n = 24). The severity of neutropenia and anaemia was graded according to the Common Terminology Criteria for Adverse Events (CTCAE v5.0). The values of the mean corpuscular volume (MCV), mean corpuscular volume hemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), and red blood cell distribution width (RDW) parameters were also taken into account. HPLC-UV method (λ = 254 nm) was applied to measure olaparib plasma concentrations. Results: There were no statistically significant differences in olaparib Ctrough between the groups — 1602.86 vs. 1567.40 ng/mL (p = 0.9156). However, the overweight and obese patients had slightly higher dose/kg-adjusted olaparib Ctrough — 204.17 vs. 159.32 ng/ml/mg/kg. The incidence of grade 1 anaemia in the groups was as follows: I — 42.86%, II — 41.67%. Grade 2 and 3 anaemia was observed only in group II — 4.17% and 8.33%, respectively. The incidence of neutropenia in the groups of patients was as follows: grade 1: group I — 21.43%, group II — 20.83%; grade 2: group I — 7.14%, group II — 4.17%. Conclusions: The incidence of haematological adverse reactions to olaparib, such as neutropenia and grade 1 anaemia in the group of overweight and obese patients was the same as in the normal BMI group. The overweight and obese patients were characterised by higher severity of haematological adverse reactions to olaparib and slightly higher dose/kg-adjusted olaparib Ctrough. After one month of treatment with olaparib the overweight and obese patients had significantly lower red blood cells (RBC) and haemoglobin (Hgb) levels than the patients with normal BMI, which may indicate that anaemia develops faster in this group of patients. Keywords: olaparib overweight obesity anaemia neutropenia Ctrough

1 January 2017
Verified
Journal Article
Closed access
AMA Markowska
A Markowska
JSJoanna Stanislawiak-Rudowicz
Joanna Stanislawiak-Rudowicz
KJK Jaszczyńska-Nowinka
K Jaszczyńska-Nowinka